Saturday, 18 April 2020

Gestational Trophoblastic Disease Market 2019 Analysis, Opportunities And Forecast To 2023

Market Scenario:
Gestational trophoblastic disease (GTD) is a cluster of rare tumors that include abnormal growth of cells inside a woman's uterus. It arises from placental trophoblastic tissue and is characterized by β-subunit of human chorionic gonadotrophin (β HCG). The increasing prevalence of risk factors such as smoking, sexually transmitted diseases (STD), history of miscarriages, and high maternal age are expected to fuel the growth of the market during the forecast period. Rise in ectopic pregnancies is also a significant factor which causes GTD. According to the National Center for Biotechnology Information (NCBI), the risk of ectopic pregnancy is 20 times higher in women who smoke. On the other hand, high risks of recurrence and complications that may occur after the therapy and treatment procedure may hinder the growth of the market during the forecast period.
The global gestational trophoblastic disease treatment market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic partnerships to strengthen its market position. For instance, in September 2018, Novartis AG entered into a license and collaboration agreement with Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company which develops therapies for cancer and degenerative diseases in Greater China.
Competitive Landscape:
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Antares Pharma
  • Mylan N.V.
  • Novartis AG
  • BP Pharmaceuticals Laboratories Company
  • Fresenius Kabi AGAccord Healthcare, Inc.
  • Eli Lilly and Company
  • Sanofi
  • Bayer AG
  • Amgen Inc.
  • Merck
Segmentation:The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.
The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.
The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease,  whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.
The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.
The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.
The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.
The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.
Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.
Posted by at No comments:
Labels:

Pulmonary Atresia Diagnostics and Treatment Market 2019 Analysis, Opportunities And Forecast To 2023

Pulmonary atresia is the type of inherited heart defect that a baby is born with. It arises when the pulmonary valve normally located between the right ventricle and the pulmonary artery doesn’t form properly. The valve should have three leaflets which allow the blood to flow forward into the pulmonary artery but prevent it from flowing backward into the right ventricle. In the case of congenital pulmonary atresia patients, the valve either malfunctions or does not form at all. The tissue formed in the place of pulmonary valve does not allow the blood flow into the pulmonary artery. This flaw develops in the first eight weeks of pregnancy and disturbs the flow of blood from the right ventricle to the pulmonary artery leading to the lungs. It can be recognized in a prenatal ultrasound.
The Global Pulmonary Atresia Diagnostics and Treatment Market Growth is expected to register a significant CAGR during the forecast period (2018–2023).
The most common symptoms are blue or gray-toned skin, troubled breathing, weakness, sleepiness, and others. Factors such as technological advancements, increasing awareness, lifestyle changes are the major driving factors for the growth of the market. However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively. 
Key Players
Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.
Segmentation
The global pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.
On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.
On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.
On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pulmonary atresia diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to the Centers for Disease Control and Prevention, congenital heart defects are a foremost cause of birth defect associated with infant illness and deaths. The deaths often occur when the infant is less than 28 days old and hence diagnosis of the defect is utmost important.
In the pulmonary atresia diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into medical devices manufacturing. According to the Centers for Disease Control and Prevention, about 40,000 births are affected by congenital heart defects in the US every year.
Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.
The market in the Middle East & Africa is expected to account for the smallest share of the global pulmonary atresia diagnostics and treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.
Posted by at No comments:
Labels:

Current And Forthcoming Fibrocystic Breasts Diagnostics and Treatment Market Size In Terms Of Volume And Value 2019

More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.
The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.
The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).
Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 
Key Players
Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.
Regional Analysis
In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.
The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Segmentation
The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Posted by at No comments:
Labels:

Digital 3D Printing Market 2019 Share, Trend, Segmentation And Forecast To 2025

Digital 3D Printing Market size is expected to register a CAGR of 20.54% to reach USD 5,214.8 Million by 2025. 3D Printing is a process in which physical objects are created by depositing materials in layers based on a digital model. The creation of a 3D printed object is achieved using additive processes. In an additive process, an object is created by laying down successive layers of materials until the object is created. 3D Printing enables to produce complex shapes using less material than traditional manufacturing methods. Each 3D Printing process requires software, hardware, and materials to work together.
Market Dynamics
Increasing applications of Digital 3D Printing in healthcare industry is expected to boost market growth. 3D Printing techniques have empowered medical practitioners, manufacturers of medical devices, as well as researchers due to their use in dental & orthodontic treatments, orthopedic implants, tissue engineering, and drug development. As a result, the increasing benefits of the mentioned applications would boost digital 3d printing market growth. 3D Printing technique is useful to speed up procedures and helps to minimize the trauma faced by patients due to conventional treatment options. Technological advancements in digital 3D Printing, rising public-private funding for 3D Printing activities are the major drivers that contribute to the growth of the digital 3D Printing market.
Segmentation
Global Digital 3D Printing Market analysis is segmented based on Component, Material, Technology, Application and End User.
The market, based on component, has been categorized as system/device and software/services. System/Device held 867.53 market value in 2018
Global digital 3D Printing market, based on material, has been segregated into polymers, metal & alloy, ceramics, and others.
Global digital 3D Printing market trends based on technology, has been segregated into stereolithography, deposition modeling, laser sintering, jetting technology, electron beam melting, and others.
Global digital 3D Printing market based on application has been categorized into dental, prosthetics, orthopedics, medical components, tissue engineering, hearing aids, drug screening, and others.
Global digital 3D Printing market, based on end user, has been segregated into hospitals & surgical centers, dental clinics & laboratories (offices), pharmaceutical & biotechnology companies, and others.
Regional Analysis
Global Digital 3D Printing Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas led the market and accounted for the largest share in 2018, owing to the existence of medical device companies and the rising prevalence of diseases along with increased adoption of treatment by patients. In North America, the US held the largest of the market share in 2018 owing to the presence of major market players, developed healthcare infrastructure, high awareness, and availability of advanced treatment options. For instance, in November 2015, a group of medical researchers from North Carolina’s Wake Forest University developed a method to print the 3D form of custom medications in the configuration of pills. As a result, increasing applications of 3D Printing is expected to drive the market growth.
Europe accounts for the second-largest share in the global digital 3D Printing market owing to the presence of favorable government initiatives & laws and target population base, rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France. Since the ban on animal testing for cosmetics in 2013, the wellness industry had been a significant supporter of 3D Printing in Europe.
Asia-Pacific is estimated to be the fastest-growing market during the forecast period due to the increasing per capita health spending, growing older population base, rising incidence of accidents, and developing the healthcare sector in China, Japan, India, and Australia.
The Middle East & Africa digital 3D Printing market is segmented into two major regions, namely the Middle East and Africa. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others. The Middle East and Africa has less economic developments and extremely low-income due to which the region accounts for the least market share but is expected to grow with the increasing cases of chronic diseases and demand for better treatments in countries.
Key Players
The Prominent Players in the Global Digital 3D Printing Market are Stratasys Ltd (US), 3D Systems, Inc. (US), Carbon, Inc. (US), EnvisionTEC (US), Formlabs (US), ExOne (US), Materialise (Europe), General Electric (US), Micron Dental (US), Renishaw PLC (UK).
Some of the key strategies followed by players operating in the Global Digital 3D Printing Market were acquisitions, expansions, product launches, partnerships, mergers, collaborations, alliances, and product approvals.
  • In June 2019, Materialise received the FDA clearance for the cardiovascular planning software suite. Thus, the suite has helped clinicians to produce patient-specific 3D models for more than 20 years.
  • In November 2019, ExOne introduced the X1 160PRO metal 3D printer for high-volume production of quality parts.
  • In February 2019, EnvisionTEC and AvaDent digital dental solutions announced a new partnership. This partnership offered a complete digital workflow solution for digital dentures, from impressions and digital design to try-in and final restoration.
Posted by at No comments:

Worldwide Hyperspectral Imaging System Market 2019 Outlook, Top 10 Industry Players Comprehensive Analysis And Forecast To 2025

Market Highlights
According to MRFR analysis, Global Hyperspectral Imaging System Market is expected to register a CAGR of 17.4% during the forecast period of 2019 to 2025 and held a value of USD 10,700 Million in 2018.
Hyperspectral imaging system has wide applications in areas such as art conservation, vegetation, water resource control, archaeology, food quality, forensic medicine, crime scene detection, and forensic medicine. HSI technology is mainly used by the defense sector, government agencies, and non-military application sectors such as agriculture and mineral.
The growth of the global hyperspectral imaging system market is boosted by various factors such as the growing industrial applications of hyperspectral imaging,  Technological advancements in electronics industry, such as sensor design, high spectral resolution, high spatial resolution, compact and lightweight devices, growing prevalence of cancer, and increasing awareness of innovative diagnostics methods.
Additionally, the introduction of innovative products in the market is expected to drive the growth of the market during the forecast period. For instance, In January 2020, Specim, Spectral Imaging Ltd. (Finland), launched Specim’s new AFX10, a compact hyperspectral camera for airborne use. Specim’s new AFX10 is easy to use and can be used to check water quality, estimating the fertilizing need in agriculture, identifying vegetation species, or studying wildlife population
However, the high cost associated with the use of hyperspectral imaging and scarcity of qualified professionals is likely to hamper the growth of the market during the forecast period.
Several market players currently dominate the global hyperspectral imaging system market. The key players are engaged in product launches and strategic collaborations to strengthen their market positions.
Regional Analysis
The Market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas held the maximum share in the year 2018, owing to the presence of established key players in countries such as the US and Canada. The hyperspectral imaging system market in the Americas has further been categorized into North America and Latin America, with the North American market further divided into the US and Canada. The European hyperspectral imaging system market has been categorized as Western Europe and Eastern Europe. The Western European market has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hyperspectral imaging system market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hyperspectral imaging system market in this region is anticipated to be the fastest growing during the assessment period due to the rising mining activities, and blooming healthcare, agriculture, and biotechnology sector in the region. The hyperspectral imaging system market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Hyperspectral Imaging System Market has been segmented based on Product, Technology, and Application.
The market, based on product, has been divided into visible/near-infrared (VNIR), short-wave infrared (SWIR), mid-wave infrared (MWIR), long-wave infrared (LWIR). The Visible/Near-Infrared (VNIR) systems segment is likely to be the largest due to the high adoption of visible/near-infrared (VNIR) systems in various industries. The mid-wave infrared (MWIR) segment is predicted to be the fastest-growing due to increasing awareness about the rising adoption of MWIR systems in detecting volcanic vents, industrial gas leaks, or biomass burning events.
The global hyperspectral imaging system market has been segmented, based on the technology, into push broom, snapshot, and others. The push broom segment is anticipated to be the largest segment during the forecast period due to the rising popularity of these devices owing to the simplified illumination requirements, minimized illumination exposure, high spectral resolution, and heat load, and the shorter capturing time.
The applications segment of the global hyperspectral imaging system market surveillance, remote sensing, machine vision/optical, and medical diagnostics. The surveillance segment is likely to hold the maximum share during the forecast period due to the rising adoption of innovative technologies in the defense sector.
Key Players
Some of the Key Players in the Global Hyperspectral Imaging System Market are Headwall Photonics, Inc. (the US), Specim, Spectral Imaging Ltd. (Finland), Norsk Elektro Optikk as (NEO) (Norway), Resonon, Inc. (the US), Corning Incorporated(US), Telops (Canada), Applied Spectral Imaging(US), Bayspec, Inc.(the US), Surface Optics Corporation (US), Chemimage Corporation (US), Cubert GmbH (Germany), Raytheon (US), Galileo Group, Inc.(the US), Hypermed Imaging, Inc.(the US), Inno-Spec (Germany), Camlin Group Ltd. (UK), IMEC (Belgium), XIMEA GmbH (Germany), among others.



Posted by at No comments:
Labels:

Friday, 17 April 2020

Medical Smart Textile Market Volume Forecast And Value Chain Analysis 2019

Market Scenario
The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new nasal drug delivery technology market, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. 
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the nasal drug delivery market growth.
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. 
Key Players
GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
Posted by at No comments:
Labels:

Biosimulation Market In Depth Study And Analysis Published, 2019

According to MRFR analysis, Biosimulation Market is expected to register a CAGR of 15.9% during the forecast period of 2019 to 2025 and is likely to be valued at USD 4.4 Billion by 2025.  
Biosimulation is a tool used for the prediction of the outcomes of existing clinical trials associated with innovation and new drug development.
The growth of the Global Biosimulation Technology Market is determined by numerous factors such as the growing adoption of biosimulation software by regulatory bodies, increasing healthcare expenditure, increasing use of pharmacokinetic & pharmacodynamic modeling in pre-clinical development and rising need to reduce the drug development costs. However, lack of standardization in biosimulation methodology and lack of trained professionals for monitoring biosimulation software are likely to hamper the growth of the global biosimulation market during the forecast period.  
Several market players currently dominate the Global Biosimulation Market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in September 2019, Certara Inc. launched version 8.2 of Phoenix, the most advanced and widely used validated software for PK, PD, and toxicokinetic modeling and simulation worldwide.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing R&D spending by pharmaceutical and biotechnology companies in the region and growing number of clinical trials & drug development practices.  
The European biosimulation market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The biosimulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Rising geriatric population and the presence of a large patient pool, are the key factors responsible for the fastest growth of the market in Asia-Pacific. The biosimulation market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Biosimulation Market has been segmented based on product, application, delivery model and end users.
The market, based on product, has been divided into software and services. The software segment is further segmented into PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation software, molecular modeling and simulation software, PBPK (physiologically based pharmacokinetic) modeling and simulation software, toxicity prediction software, trial design software, and others. The services segment is further segmented into in-house services and contract services. The software segment is likely to hold the maximum market share in the global biosimulation market owing to growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.
The global biosimulation market based on the application has been segregated into drug development, drug discovery, and others. The drug development segment is expected to hold a larger share of the market share owing to the rising adoption of biosimulation tool for the drug development process.
The delivery model segment of the market is divided into subscription models and ownership models.
Based on end users, the global biosimulation market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, research institutes, regulatory authorities, and others. Rising adoption of inorganic growth strategies by different biosimulation service providers is likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology companies.
Key Players
Some of the Key Players in the Global Biosimulation Market are Dassault Systèmes (France), Certara USA, Inc. (US), Simulation Plus (US), Schrödinger (US), Chemical Computing Group (Canada), Physiomics (UK), In Silico Biosciences (US), Advanced Chemistry Development, Inc. (Canada), Genedata AG (Switzerland), Nuventra Pharma (US), Evidera (US), Leadinvent Technologies (India), LeadScope, Inc. (US), Rosa (US) and INOSIM Software GmbH (Germany).
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)